# Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

> **NCT02638389** · PHASE3 · RECRUITING · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 250 (estimated)

## Conditions studied

- Vascular Malformations

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02638389
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-01-25
- **Primary completion:** 2025-04-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02638389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02638389, "Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02638389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*